Huons said Monday that it is speeding up installing ExAblate Neuro to Samsung Medical Center (SMC) in September to provide magnetic resonance-guided focused ultrasound surgery (MRgFUS) for those with brain diseases.

Huons acquired exclusive rights to supply ExAblate Neuro developed by the Israeli biotechnology company Insightec in 2019. The device uses a non-invasive surgical method to remove the specific tissue that causes abnormal brain function by using MRgFUS, unlike the existing therapy that requires cutting a bony opening in the skull.

The device has no risk of bleeding or infection, and the surgeons can monitor the surgical site in real-time through MRI images while performing an operation. Patients who receive surgery with ExAblate Neuro recover rapidly and return to their usual daily activities.

“If Huons installs the device at SMC, people with brain disorders will receive safer operations,” Huons said.

Regulatory agencies in 23 countries, including the U.S. Food and Drug Administration, have authorized ExAblate Neuro, and 82 hospitals and other medical institutions are using the device, it added.

“ExAblate Neuro is a new device that has shown excellent therapeutic effect for brain diseases, such as tremor,” Samsung Medical Center Neurosurgery Department Professor Lee Jung-il said. “We are glad to introduce a novel, cutting-edge treatment system that has drawn the attention of the neurosurgery communities worldwide.”

Ori Atar, the director of Insightec’s Asian Growth Markets, said, “We are pleased to supply ExAblate Neuro to Samsung Medical Center that provides excellent patient-centered medical services in Korea.”

Ori Atar added that the company expects ExAblate Neuro to become a new treatment option in Korea, stressing the effectiveness of treatment for brain diseases has been proven globally with studies of various illnesses.

Huons CEO Eom Gi-an also said. “Korean patients can receive therapies for brain disease using ExAbalte Neuro, as Samsung Medical Center decided to install the device. We will provide more treatment options for patients.”